Marvel Biosciences to Give Oral Presentation at the Annual IRSF Rett Syndrome Scientific Meeting
Calgary, Alberta – April 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL, OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together “Marvel”), are pleased to announce their acceptance to give an oral presentation at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer of Marvel, will...
Marvel Biosciences Selected to Present Alzheimer’s Research at the 2025 Alzheimer’s Association International Conference
Calgary, Alberta – April 14, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer’s Association International Conference (AAIC), taking place in July 2025. The Company will present...
Marvel Biosciences Announces Private Placement
Calgary, Alberta, Canada, March 28, 2025 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that, subject to approval of the TSX Venture Exchange (the “TSXV”), it has closed the first tranche of a non-brokered private placement of up to 12,000,000 units (the “Units”) at a price of...
Marvel Biosciences to File for Orphan Drug Designation with the U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Calgary, Alberta – March 17, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for its lead compound, MB-204, as a potential treatment for Rett Syndrome. This decision follows strong...
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
Calgary, Alberta – March 13, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. The study evaluated MB-204, Marvel’s lead compound (10 mg/kg oral once...
Marvel Presenting at the 2025 Bloom Burton & Co. Conference
Calgary, Alberta – March 11, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, on May 5 and...
Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China
Calgary, Alberta – January 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce that the Chinese patent office has issued a notice of allowance for its lead compound MB-204. This is the first allowance worldwide for this family. “We are pleased with this...
Marvel Biosciences Announces Private Placement For Up To $2.5 Million
Calgary, Alberta - January 7, 2025 - Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of common shares of the Company (each a “Common Share”) at a price of $0.15 per Common Share for gross proceeds of a minimum of $1,935,000 and up to a maximum of $2,500,000 (the “Offering”). It...
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA
Calgary, Alberta – November 26, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share additional data from its ongoing preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. Marvel also announces plans to engage with the FDA to discuss these...
Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer’s Research
Calgary, Alberta – November 21, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it has been awarded the Alberta Innovates AICE Validates grant, securing $300,000 in funding to support the preclinical validation of MB204 as a treatment for Alzheimer’s disease....